Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRML vs TNON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TNON Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–3 Matrix Metrics)

TNON Overall Winner 6-Pillar Tally: GRML 1 – 3 TNON (2 Tie) Matrix Metrics: GRML 3 – 5 TNON

As of Nov 16, 2026, Tenon Medical, Inc. (TNON) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GRML carries a Unified Composite Score of 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin), whereas TNON carries 45.0/100 (HOLD) at $1.32 (N/M Forward P/E, -228.0% operating margin).

  • Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. TNON 45.0/100 HOLD), TNON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-228.0% vs. N/A operating margin) and revenue trajectory (+126.8% vs. N/A YoY).
  • Technical & Structure Timing Caution: GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5); meanwhile TNON is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRML vs TNON
GRML US Equity
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -5.32β · 95% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 37.5 · SMA20: $4.67 · SMA50: $6.11
TNON NASDAQ Head-to-Head Winner
Tenon Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.32
-6.03% 1D
Market Cap $3.8M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol -1.56β · 106% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 33.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.3%), weak momentum, RSI 27
RSI-14: 27.5 · SMA20: $1.96 · SMA50: $2.95

6-Pillar Scorecard Institutional Category Breakdown (GRML 1 – 3 TNON)

Columns: Metric · GRML · TNON
1. Valuation Multiples TNON
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 1.5x
2. Growth & Scale TNON
Revenue Growth (YoY) N/A +126.8%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $5.3M
Market Cap N/A $3.8M
3. Profitability & Quality TNON
Gross Margin N/A 66.8%
Operating Margin N/A -228.0%
Net Profit Margin N/A -257.9%
Return on Equity (ROE) N/A -551.2%
4. Balance Sheet & Cash Flow GRML
Cash Generation (TTM) N/A -$12M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $4.0M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRML (3) vs TNON (5)
Institutional Metric GRML TNON Criterion Row Edge
Market Capitalization
Scale
N/A $3.8M Larger Scale TNON
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +126.8% Higher Growth TNON
Operating Margin (TTM)
Profitability
N/A -228.0% Higher Margin TNON
Net Profit Margin
Profitability
N/A -257.9% Higher Margin TNON
Return on Equity (ROE)
Capital Efficiency
N/A -551.2% Higher ROE TNON
52-Week Range Position
Momentum
19% ($0–$18) 7% ($0–$18) Stronger Trend GRML
Beta / 30D Volatility
Risk Regime
-5.32β · 95% Vol -1.56β · 106% Vol Lower Realized Risk GRML
Unified Institutional Score
Composite Signal
56.8 / 100 (HOLD) 45.0 / 100 (HOLD) Higher Composite GRML
Trailing 12M Revenue (USD)
Operating Scale
N/A $5.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 66.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$12M EBITDA ($4.0M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRML +9.43 pp
GRML: -41.5% · TNON: -50.93%
3M Horizon GRML +1842.71 pp
GRML: +1767.02% · TNON: -75.69%
6M Horizon GRML +801.63 pp
GRML: +894.05% · TNON: +92.42%
1Y Horizon GRML +585.44 pp
GRML: +650.0% · TNON: +64.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRML vs TNON. Trailing 12-month operating profitability (GRML N/A vs TNON -228.0%) and valuation multiples (GRML N/M vs TNON N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GRML ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
TNON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.3M
Gross Margin66.8%
Op. Margin-228.0%
ROE / Fwd P/E-551.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRML UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GRML Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TNON UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TNON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRML Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TNON Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.8M market capitalization and -228.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GRML vs TNON Key Questions & Quantitative Answers

As of Nov 16, 2026, Tenon Medical, Inc. (TNON) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GRML carries a Unified Composite Score of 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin), whereas TNON carries 45.0/100 (HOLD) at $1.32 (N/M Forward P/E, -228.0% operating margin). Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. TNON 45.0/100 HOLD), TNON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-228.0% vs. N/A operating margin) and revenue trajectory (+126.8% vs. N/A YoY). Technical & Structure Timing Caution: GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5); meanwhile TNON is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TNON leads the Growth & Scale pillar: GRML posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with TNON at +126.8% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (66.8% gross margin, -228.0% operating margin). On trailing 12-month operating scale, GRML generates N/A in USD-normalized revenue versus $5.3M for TNON. In operating R&D and SG&A reinvestment, GRML deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TNON.

TNON screens cheaper on headline valuation multiples. GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas TNON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRML (N/A ROE) versus TNON (-551.2% ROE) capital efficiency.

In options market volatility and institutional positioning, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.32β · 95% Vol realized risk). By comparison, TNON carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.56β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.